ORCID Profile
0000-0002-9060-7601
Current Organisation
University of New South Wales - Randwick Campus
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 24-02-2021
DOI: 10.1111/DAR.13252
Abstract: This paper aims to describe cocaine use, markets and harms in Australia from 2003 to 2019. Outcome indicators comprised prevalence of use from triennial household surveys patterns of use from annual surveys of sentinel s les who use stimulants and cocaine‐related seizures, arrests, hospitalisations, deaths and treatment episodes. Bayesian autoregressive time‐series analyses were conducted to estimate trend over time: Model 1, no change Model 2, constant rate of change and Model 3, change over time differing in rate after one change point. Past‐year population prevalence of use increased over time. The percentage reporting recent use in sentinel s les increased by 6.1% (95% credible interval [CrI 95% ] 1.2%,16.9% Model 3) per year from around 2017 (48%) until the end of the series (2019: 67%). There was a constant annual increase in number of seizures (count ratio: 1.1, CrI 95% 1.1,1.2) and arrests (1.2, CrI 95% 1.1,1.2), and percentage reporting cocaine as easy to obtain in the sentinel s les (percent increase 1.2%, CrI 95% 0.5%,1.8% Model 2). Cocaine‐related hospitalisation rate increased from 5.1 to 15.6 per 100 000 people from around 2011–2012 to 2017–2018: an annual increase of 1.3 per 100 000 people (CrI 95% 0.8,1.8 Model 3). While the death rate was low (0.23 cocaine‐related deaths per 100 000 people in 2018 Model 2), treatment episodes increased from 3.2 to 5.9 per 100 000 people from around 2016–2017 to 2017–2018: an annual increase of 2.9 per 100 000 people (CrI 95% 1.6,3.7 Model 3). Cocaine use, availability and harm have increased, concentrated in recent years, and accompanied by increased treatment engagement.
Publisher: Public Library of Science (PLoS)
Date: 08-03-2018
Publisher: Elsevier BV
Date: 10-2017
Publisher: Wiley
Date: 23-05-2022
DOI: 10.1111/DAR.13468
Abstract: To describe trends in meth hetamine use, markets and harms in Australia from 2003 to 2019. Data comprised patterns of use and price from sentinel s les of people who inject drugs and who use MDMA/other illicit stimulants and population‐level hetamine‐related police seizures, arrests, hospitalisations, treatment episodes and deaths from approximately 2003 to 2019. Bayesian autoregressive time‐series models were analysed for: no change constant rate of change and change over time differing in rate after one to three changepoints. Related indicators were analysed post hoc with identical changepoints. The percentage of people who inject drugs reporting weekly use increased from 2010 to 2013 onwards, while use among s les of people who regularly use ecstasy and other illicit stimulants decreased. Seizures and arrests rose steeply from around 2009/10 to 2014/15 and subsequently plateaued. Price increased ($15.9 [95% credible interval, CrI $9.9, $28.9] per point of crystal per year) from around 2009 to 2011, plateauing and then declining from around 2017. Hospitalisation rates increased steeply from around 2009/10 until 2015/16, with a small subsequent decline. Treatment also increased (19.8 episodes [95% CrI 13.2, 27.6] with hetamines as the principal drug of concern per 100 000 persons per year) from 2010/11 onwards. Deaths involving hetamines increased (0.285 per 100 000 persons per year) from 2012 until 2016. These findings suggest that problematic meth hetamine use and harms escalated from 2010 to 2012 onwards in Australia, with continued demand and a sustained market for meth hetamine. [Correction added on 30 May 2022, after first online publication: In the Abstract under ‘Discussion and Conclusions’ ‘onwards’ has been added after … 2010 to 2012].
Publisher: Elsevier BV
Date: 09-2016
No related grants have been discovered for Edgar Gomez.